Deanna McLeod (Part 2)
In her second appearance, medical-research analyst Deanna McLeod presents Ontario health data (physician billing and cancer-registry records) showing spikes in heart inflammation, blood clots and cancers, arguing the mRNA products bypassed proper safety testing.
Key points
- Deanna McLeod, of Kaleidoscope Strategic medical research firm with 20 years of evidence-based evaluation experience, resumes her presentation of population-level health data.
- She presents Ontario OHIP billing data for 16 million people showing elevated care-seeking for Bell's palsy following the mRNA vaccine rollout, above chance-level bands.
- She reports a 13% increase in hospital pulmonary embolisms and myocarditis increases of 87% and 76%, arguing myocarditis was not merely rare and transient.
- She argues the mRNA products were approved on only two months of trial data via emergency rolling reviews, monitoring harm rather than proving safety.
- She presents SEER cancer registry and health-seeking data suggesting increases in breast, uterine, ovarian, and cervical cancers, especially metastatic cases in women under 50.
- She contends the products were regulated as vaccines despite acting as gene therapy, resulting in lower safety-testing standards.
- She argues inflated projections based on China's data triggered public health orders that gave one chief medical officer authority to direct all provincial healthcare workers.
Shawn Buckley
Deanna McLeod
Shawn Buckley
Deanna McLeod
Shawn Buckley
Deanna McLeod
Shawn Buckley
Deanna McLeod
Shawn Buckley
Deanna McLeod
Shawn Buckley
Deanna McLeod
Shawn Buckley